Results 141 to 150 of about 3,877 (197)

Is Rituximab Suitable for Patients with Idiopathic Membranous Nephropathy Who are Seronegative for Anti-PLA2R Antibody? [PDF]

Drug Des Devel Ther
Yang Y, Xie X, Yuan F, Zeng F, Wang Y, Zhang R, Yan W, Luo K, Ren D, Xu G.   +9 more
europepmc   +1 more source

Transcriptomic analysis of differential expression and correlation of coding and non-coding RNAs in urine from patients with idiopathic membranous nephropathy. [PDF]

Biol Direct
Li J, Zhou Z, Wu R, Chen Q.
europepmc   +1 more source

The clinical features of anti-CNTN1 antibodies associated autoimmune nodopathies with nephropathy: a case series. [PDF]

Front Neurol
Wan J, Xiong T, Hu J, Liu S, Lin J, Zhao C, Sun C, Xiao H.   +7 more
europepmc   +1 more source

The value of proteinuria for the administration of rituximab in patients with PLA2R-associated membranous nephropathy: a single-centre retrospective analysis. [PDF]

Ann Med
Li X, Zhang Y, Xu C, Ke B.
europepmc   +1 more source

Efficacy of immunosuppressive therapy in low-risk and intermediate- risk idiopathic membranous nephropathy patients : a 2-year follow-up study. [PDF]

BMC Nephrol
Jin Y, Zhang Y, Chen W, Lan L, Chen C, Jiang J, Jiang J.   +6 more
europepmc   +1 more source

Obinutuzumab is effective for refractory primary membranous nephropathy. [PDF]

BMC Nephrol
Zhao N, Chen P, Chen J, Wang B, Tang X, Tang L, Wang Z, Zhang Y.   +7 more
europepmc   +1 more source

Clinical effect of obinutuzumab in the treatment of idiopathic membranous nephropathy. [PDF]

Am J Transl Res
Ning S, Zhang Q, Shang Z, Liu H.
europepmc   +1 more source

Anti-PLA2R antibody reduction as a predictor of treatment response in primary membranous nephropathy: a retrospective study. [PDF]

J Bras Nefrol
Bashir K, Asghar MR, Saleem N, Shahzil M, Riaz A, Hashmi MN, Sheraz A.   +6 more
europepmc   +1 more source